Johnson & Johnson (NYSE:JNJ) has long been a favorite among dividend growth investors, and for good reason. With 54 straight years of rising dividends, JNJ has delivered spectacular, market crushing total returns over the decades.
JNJ Total Return Price data by YCharts
However, thanks to yield hungry investors bidding up the share price over the past year far more than rivals such as Pfizer (NYSE:PFE) and Merck (NYSE:MRK), Johnson & Johnson is now overvalued; especially relative to its realistic future dividend growth prospects.
